Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This study reported that while various treatments for frontal fibrosing alopecia showed limited effectiveness, dutasteride most effectively stabilized the condition among patients at Duke University.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This article discusses the FDA's decision not to approve 5α-reductase inhibitors for prostate cancer prevention, citing an increase in high-grade tumors but no mortality evidence, and reports no new results.

This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.

In this study, ethanol was found to enhance GABAergic neurosteroid production and inhibit long-term potentiation in rat hippocampal slices via unblocked NMDA receptor activation, effects reversible by specific inhibitors.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

New treatments for male hypogonadism are effective and should be personalized.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study classified frontal fibrosing alopecia patients into three clinical patterns, finding that pattern III had the best prognosis and pattern II the worst after treatment with dutasteride and corticosteroids.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This article reviews current knowledge on the causes, diagnosis, and medical treatments for androgenetic alopecia, particularly in men, and reports no new findings.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

In this study, manipulation of the enzyme 5α-reductase type 2 in human hepatocytes altered lipogenesis, suggesting clinical implications for patients using 5α-reductase inhibitors by affecting glucocorticoid action on hepatic lipid metabolism.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

This review concluded that monoclonal antibodies are currently the most effective treatment for COVID-19, with potential efficacy of high-titer convalescent plasma when used early, while multiple other drugs require further evaluation to determine their effectiveness.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review highlights the need for tailored hormonal treatment strategies for non-binary transgender individuals, emphasizing personalized care to enhance psychological well-being and quality of life.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

This study found that dual 5α-reductase inhibitors in rats decreased sperm quality and led to reduced pregnancy success, suggesting potential for use in male contraception.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.